G1 THERAPEUTICS INC's ticker is GTHX and the CUSIP is 3621LQ109. A total of 95 filers reported holding G1 THERAPEUTICS INC in Q1 2019. The put-call ratio across all filers is 0.97 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $744,089 | +437.5% | 516,728 | +829.4% | 0.00% | – |
| Q2 2023 | $138,444 | -93.2% | 55,600 | -92.7% | 0.00% | -100.0% |
| Q1 2023 | $2,045,848 | -62.1% | 763,376 | -23.3% | 0.00% | -66.7% |
| Q4 2022 | $5,402,787 | -31.6% | 994,988 | +57.4% | 0.01% | -29.4% |
| Q3 2022 | $7,895,000 | +235.2% | 632,178 | +32.6% | 0.02% | +240.0% |
| Q2 2022 | $2,355,000 | +212.7% | 476,822 | +381.5% | 0.01% | +400.0% |
| Q1 2022 | $753,000 | +58.9% | 99,021 | +451.8% | 0.00% | -66.7% |
| Q4 2019 | $474,000 | -91.8% | 17,944 | -90.5% | 0.00% | -93.8% |
| Q2 2019 | $5,809,000 | +106.0% | 189,486 | +11.6% | 0.05% | +269.2% |
| Q1 2019 | $2,820,000 | -61.9% | 169,848 | -56.1% | 0.01% | -82.9% |
| Q4 2018 | $7,402,000 | +62.6% | 386,510 | +344.1% | 0.08% | +300.0% |
| Q3 2018 | $4,552,000 | – | 87,040 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| MPM BioImpact LLC | 1,423,794 | $34,541,000 | 9.18% |
| Burrage Capital Management LLC | 373,876 | $9,070,000 | 6.35% |
| Birchview Capital, LP | 40,000 | $970,000 | 0.59% |
| 361 CAPITAL LLC | 47,325 | $1,148,000 | 0.54% |
| Rhenman & Partners Asset Management AB | 190,000 | $4,609,000 | 0.50% |
| CHI Advisors LLC | 44,000 | $1,067,000 | 0.42% |
| Bellevue Group AG | 721,925 | $17,514,000 | 0.25% |
| Candriam S.C.A. | 870,423 | $21,117,000 | 0.22% |
| Virtus ETF Advisers LLC | 18,991 | $461,000 | 0.22% |
| HHLR ADVISORS, LTD. | 949,431 | $23,033,000 | 0.21% |